

Access DB# 92709

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Gerstl Examiner #: 59472 Date: 4/24/03
Art Unit: 1676 Phone Number 301 4531 Serial Number: 691895812
Mail Box and Bldg/Room Location: 3B09 Results Format Preferred (circle): PAPER DISK E-MAIL


If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____
Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov


BEST AVAILABLE COPY

STAFF USE ONLY		Type of Search	Vendors and cost where applicable
Searcher: <u>[Signature]</u>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/>	
Searcher Phone #: <u>4498</u>	AA Sequence (#) _____	Dialog _____	
Searcher Location: _____	Structure (#) <input checked="" type="checkbox"/>	Questel/Orbit _____	
Date Searcher Picked Up: <u>4/24/03</u>	Bibliographic <input checked="" type="checkbox"/>	Dr.Link _____	
Date Completed: <u>4/24/03</u>	Litigation _____	Lexis/Nexis _____	
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____	
Clerical Prep Time: <u>10</u>	Patent Family _____	WWW/Internet _____	
Online Time: <u>0</u>	Other _____	Other (specify) _____	

BioTech-Chem Library

Search Results

Feedback Form (Optional)



Scientific & Technical Information Center

The search results generated for your recent request are attached. If you have any questions or comments (compliments or complaints) about the scope or the results of the search, please contact *the BioTech-Chem searcher* who conducted the search *or contact*:

Mary Hale, Supervisor, 308-4258
CM-1 Room 1E01

Voluntary Results Feedback Form

➤ *I am an examiner in Workgroup:* (Example: 1610)

➤ *Relevant prior art found, search results used as follows:*

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ *Relevant prior art not found:*

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Search results were not useful in determining patentability or understanding the invention.

Other Comments:

Drop off completed forms at the Circulation Desk CM-1, or send to Mary Hale, CM1-1E01 or e-mail mary.hale@uspto.gov.

=> fil reg

FILE 'REGISTRY' ENTERED AT 12:18:00 ON 29 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

DICTIONARY FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 16

L1 STR



VAR G1=C/O/N/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1


NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L3 166 SEA FILE=REGISTRY SSS FUL L1

L4 STR

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov



VAR G1=C/O/N/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS UNS AT 19
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 2
 NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
 L6 91 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

100.0% PROCESSED 166 ITERATIONS
 SEARCH TIME: 00.00.01

91 ANSWERS

=> d his l6-

(FILE 'REGISTRY' ENTERED AT 12:12:19 ON 29 APR 2003)
 L6 91 S L4 FUL SUB=L3
 SAV L6 GERSTL895A/A TEMP
 L7 75 S L3 NOT L6

FILE 'HCAPLUS' ENTERED AT 12:15:00 ON 29 APR 2003
 L8 9 S L6
 L9 6 S L7
 L10 6 S L8 AND L9
 L11 9 S L8-L10
 L12 9 S L11 AND (NELSON ? OR FRECHETTE ? OR VISKI ? OR ISMAIL ? OR BO

FILE 'HCAPLUS' ENTERED AT 12:17:19 ON 29 APR 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 12:17:23 ON 29 APR 2003
 L13 3 S L6
 L14 2 S L7
 L15 3 S L13,L14

FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:17:39 ON 29 APR 2003
 L16 12 DUP REM L12 L15 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 12:18:00 ON 29 APR 2003

=> fil uspatall
 FILE 'USPATFULL' ENTERED AT 12:18:15 ON 29 APR 2003
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:18:15 ON 29 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d 115 bib abs hitrn fhitr tot

L15 ANSWER 1 OF 3 USPATFULL
AN 2003:79098 USPATFULL
TI 7-substituted tetracycline compounds
IN Nelson, Mark L., Wellesley, MA, UNITED STATES
Frechette, Roger, Reading, MA, UNITED STATES
Viski, Peter, Brookline, MA, UNITED STATES
Ismail, Mohamed, Bedford, MA, UNITED STATES
Bowser, Todd, Charlton, MA, UNITED STATES
Bhatia, Beena, Arlington, MA, UNITED STATES
Messersmith, David, Somerville, MA, UNITED STATES
McIntyre, Laura, Arlington, MA, UNITED STATES
Koz, Darrell, Westerly, RI, UNITED STATES
Rennie, Glen, Weymouth, MA, UNITED STATES
Sheahan, Paul, Hopkinton, MA, UNITED STATES
Hawkins, Paul, Cambridge, MA, UNITED STATES
Verma, Atul, Arlington, MA, UNITED STATES
Warchol, Tadeusz, Acton, MA, UNITED STATES
Bandarage, Upul, Newton, MA, UNITED STATES
PI US 2003055025 A1 20030320
AI US 2001-895812 A1 20010629 (9)
PRAI US 2001-275576P 20010313 (60)
US 2000-216760P 20000707 (60)
DT Utility
FS APPLICATION
LREP Elizabeth A. Hanley, Esq., Lahive & Cockfield, LLP, 28 State Street,
Boston, MA, 02109
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains, at least in part, to novel 7-substituted
tetracycline compounds. These tetracycline compounds can be used to
treat numerous tetracycline compound-responsive states, such as
bacterial infections and neoplasms, as well as other known applications
for minocycline and tetracycline compounds in general, such as blocking
tetracycline efflux and modulation of gene expression.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **389624-36-6P**
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as
antibacterial agents)
IT **389623-84-1P 389623-86-3P 389623-89-6P**
389623-90-9P 389623-91-0P 389623-98-7P
389623-99-8P 389624-00-4P 389624-01-5P
389624-02-6P 389624-06-0P 389624-08-2P
389624-09-3P 389624-10-6P 389624-11-7P
389624-14-0P 389624-15-1P 389624-16-2P
389624-17-3P 389624-18-4P 389624-19-5P
389624-20-8P 389624-25-3P 389624-26-4P
389624-27-5P 389624-30-0P 389624-31-1P
389624-32-2P 389624-33-3P 389624-35-5P
389624-37-7P 389624-38-8P 389624-39-9P
389624-40-2P 389624-41-3P 389624-42-4P
389624-43-5P 389624-44-6P 389624-46-8P
389624-47-9P 389624-48-0P 389624-49-1P
389624-50-4P 389624-51-5P 389624-52-6P
389624-53-7P 389624-56-0P 389624-60-6P

389624-61-7P 389624-62-8P 389624-63-9P
 389624-64-0P 389624-65-1P 389624-66-2P
 389624-67-3P 389624-68-4P 389624-70-8P
 389624-71-9P 389624-72-0P 389624-73-1P
 389624-74-2P 389624-75-3P 389624-76-4P
 389624-77-5P 389624-78-6P 389624-79-7P
 389624-80-0P 389624-83-3P 389624-84-4P
 389624-85-5P 389624-86-6P 389624-87-7P
 389624-88-8P 389624-89-9P 389624-95-7P
 389624-96-8P

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)


IT 389624-36-6P

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RN 389624-36-6 USPTAFULL

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(3-methoxyphenyl)ethynyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 2 OF 3 USPTAFULL

AN 2002:337989 USPTAFULL

TI 7, 9-substituted tetracycline compounds

IN Nelson, Mark L., Wellesley, MA, UNITED STATES
 Frechette, Roger, Reading, MA, UNITED STATES
 Viski, Peter, Brookline, MA, UNITED STATES
 Ismail, Mohamed, Bedford, MA, UNITED STATES
 Bowser, Todd, Charlton, MA, UNITED STATES
 McIntyre, Laura, Arlington, MA, UNITED STATES
 Bhatia, Beena, Arlington, MA, UNITED STATES
 Hawkins, Paul, Cambridge, MA, UNITED STATES
 Reddy, Laxma, Lexington, MA, UNITED STATES
 Stapleton, Karen, Weymouth, MA, UNITED STATES
 Warchol, Tad, Acton, MA, UNITED STATES
 Sheahan, Paul, Hopkinton, MA, UNITED STATES

PI US 2002193354 A1 20021219

AI US 2001-895797 A1 20010629 (9)

PRAI US 2001-275620P 20010313 (60)

DT Utility

FS APPLICATION

LREP Elizabeth A. Hanley, Esq., Lahive & C  ckfield, LLP, 28 State Street,
 Boston, MA, 02109

CLMN Number of Claims: 61

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 459810-04-9P

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 459809-43-9P 459809-46-2P 459809-47-3P

459809-48-4P 459809-51-9P 459809-54-2P

459809-56-4P 459809-58-6P 459809-61-1P

459809-63-3P 459809-65-5P 459809-67-7P

459809-70-2P 459809-72-4P 459809-81-5P

459809-86-0P 459809-92-8P 459809-94-0P

459809-99-5P 459810-03-8P 459810-05-0P

459810-06-1P 459810-09-4P

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 263761-05-3P, 7-Ethynylsancycline 389624-14-0P,

7-Ethylsancycline 459810-10-7P

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)


IT 459810-04-9P

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RN 459810-04-9 USPTFULL

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-iodo-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 3 USPTFULL

AN 2002:206638 USPTFULL

TI 7,8 and 9-substituted tetracycline compounds

IN Nelson, Mark L., Wellesley, MA, UNITED STATES

Koza, Darrell, Westerly, RI, UNITED STATES

PI US 2002111335 A1 20020815

AI US 2001-894805 A1 20010629 (9)

PRAI WO 2000-US21366 20000804

US 2000-216656P 20000707 (60)

DT Utility

FS APPLICATION

LREP LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1042

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 263761-03-1P 389570-50-7P 389570-53-0P

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)


IT 263761-03-1P

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

RN 263761-03-1 USPATFULL

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 12:18:28 ON 29 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Apr 2003 VOL 138 ISS 18

FILE LAST UPDATED: 28 Apr 2003 (20030428/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitr tot 112

L12 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2003:57866 HCAPLUS

DN 138:117673

TI Tetracycline compounds having target therapeutic activities

IN Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham

PA Paratek Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

ICI A61

CC 1-12 (Pharmacology)

Section cross-reference(s): 26

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003005971	A2	20030123	WO 2002-US22451	20020715
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-305546P P 20010713

OS MARPAT 138:117673

AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compd. prepn.

ST tetracycline compd prepn therapeutic

IT Brain, disease

Prion diseases

(Creutzfeldt-Jakob; tetracycline compds. with target therapeutic activities)

IT Nervous system

(GABAergic, GABAergic therapy; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Brain, disease

(Gilles de la Tourette syndrome; tetracycline compds. with target therapeutic activities)

IT Nervous system

(Huntington's chorea; tetracycline compds. with target therapeutic activities)

IT Wernicke-Korsakoff syndrome

(Korsakoff's psychosis; tetracycline compds. with target therapeutic activities)

IT Amnesia

(Korsakoff's; tetracycline compds. with target therapeutic activities)

IT Glutamate antagonists

(NMDA antagonists; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Inflammation

Respiratory distress syndrome

(acute; tetracycline compds. with target therapeutic activities)

IT Respiratory distress syndrome

(adult; tetracycline compds. with target therapeutic activities)

IT Nervous system

(amyotrophic lateral sclerosis; tetracycline compds. with target therapeutic activities)

IT Artery, disease
(aneurism; tetracycline compds. with target therapeutic activities)

IT Antiarteriosclerotics
(antiatherosclerotics; tetracycline compds. with target therapeutic activities)

IT Artery, disease
(aorta, aneurism; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(attention deficit disorder; tetracycline compds. with target therapeutic activities)

IT Glycosylation
(biol., protein; tetracycline compds. with target therapeutic activities)

IT Bone, disease
(bone mass disorder; tetracycline compds. with target therapeutic activities)

IT Bronchi
(bronchiectasis; tetracycline compds. with target therapeutic activities)

IT Bronchi, disease
(bronchitis; tetracycline compds. with target therapeutic activities)

IT Ion channel blockers
(calcium; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Musculoskeletal diseases
(cartilage, degrdn.; tetracycline compds. with target therapeutic activities)

IT Lung, disease
(chronic obstructive; tetracycline compds. with target therapeutic activities)

IT Inflammation
Lung, disease
(chronic; tetracycline compds. with target therapeutic activities)

IT Animal cell
(compds. increasing energy available to cells; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Eye, disease
(cornea, ulcer; tetracycline compds. with target therapeutic activities)

IT Antiulcer agents
(corneal ulceration; tetracycline compds. with target therapeutic activities)

IT Bone, disease
(degrdn.; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(dementia, Alzheimer's disease-related; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(depression, major; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(depression, neurotic; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(depression; tetracycline compds. with target therapeutic activities)

IT Disease, animal
(diabetic complications; tetracycline compds. with target therapeutic activities)

IT Ulcer
(diabetic; tetracycline compds. with target therapeutic activities)

IT Cartilage
(disease, degrdn.; tetracycline compds. with target therapeutic activities)

activities)
IT Nervous system
 (disease; tetracycline compds. with target therapeutic activities)
IT Learning
 Sleep
 (disorder; tetracycline compds. with target therapeutic activities)
IT Eye, disease
 (dry; tetracycline compds. with target therapeutic activities)
IT Drugs
 (gastrointestinal; tetracycline compds. with target therapeutic activities)
IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glycosylation; tetracycline compds. with target therapeutic activities)
IT Disease, animal
 (inflammation process-assocd. state; tetracycline compds. with target therapeutic activities)
IT Lung, disease
 (injury, acute; tetracycline compds. with target therapeutic activities)
IT Brain, disease
 Nerve, disease
 (injury; tetracycline compds. with target therapeutic activities)
IT Diabetes mellitus
 (insulin-dependent; tetracycline compds. with target therapeutic activities)
IT Mental disorder
 (mania; tetracycline compds. with target therapeutic activities)
IT Mental disorder
 (manic bipolar disorder; tetracycline compds. with target therapeutic activities)
IT Neoplasm
 (metastasis; tetracycline compds. with target therapeutic activities)
IT Headache
 (migraine; tetracycline compds. with target therapeutic activities)
IT Nerve, disease
 (motor; tetracycline compds. with target therapeutic activities)
IT Nerve
 (neuron, neuronal membrane stabilizers; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Membrane, biological
 (neuronal membrane stabilizers; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Cytoprotective agents
 (neuroprotectants; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Mental disorder
 (obsession-compulsion; tetracycline compds. with target therapeutic activities)
IT Bone, neoplasm
 (osteosarcoma; tetracycline compds. with target therapeutic activities)
IT Anxiety
 (panic disorder; tetracycline compds. with target therapeutic activities)
IT Periodontium
 (periodontitis; tetracycline compds. with target therapeutic activities)
IT Mental disorder
 (phobia; tetracycline compds. with target therapeutic activities)
IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyunsatd., n-3; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein buildup removal agents; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Paralysis
(pseudobulbar; tetracycline compds. with target therapeutic activities)

IT Transcription, genetic
(regulators; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Artery, disease
(restenosis; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(schizoaffective disorder; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(senile psychosis; tetracycline compds. with target therapeutic activities)

IT Respiratory tract
(sinusitis; tetracycline compds. with target therapeutic activities)

IT Ion channel blockers
(sodium; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Brain, disease
(stroke; tetracycline compds. with target therapeutic activities)

IT Aging, animal
Alzheimer's disease
Amnesia
Aneurysm
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiartherosclerotics
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihypertensives
Antimalarials
Antimigraine agents
Antipsychotics
Antirheumatic agents
Antitumor agents
Antiviral agents
Anxiety
Anxiolytics
Arteriosclerosis
Asthma
Atherosclerosis
Autoimmune disease
Carcinoma
Cardiovascular agents
Cognition enhancers
Cystic fibrosis
Diabetes mellitus
Drug delivery systems
Emphysema
Epilepsy

Escherichia coli
Eye, disease
Fungicides
Hepatitis
Human
Hypertension
Inflammation
Ischemia
Lung, disease
Macrophage
Malaria
Mental disorder
Multiple sclerosis
Neoplasm
Nervous system agents
Osteoarthritis
Osteomyelitis
Osteoporosis
Parasitocides
Psychotropics
Rheumatoid arthritis
Sarcoma
Schizophrenia
Skin, disease
Staphylococcus aureus
Wound healing promoters
 (tetracycline compds. with target therapeutic activities)
IT Tetracyclines
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (tetracycline compds. with target therapeutic activities)
IT Anti-infective agents
 Antioxidants
 Chemotherapy
 Ginkgo biloba
 Opioid antagonists
 Radiotherapy
 (tetracycline compds. with target therapeutic activities, and use with
 other agents)
IT Glucocorticoids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (tetracycline compds. with target therapeutic activities, and use with
 other agents)
IT Wound
 (tissue; tetracycline compds. with target therapeutic activities)
IT Brain, disease
 Spinal cord
 (trauma; tetracycline compds. with target therapeutic activities)
IT Intestine, disease
 (ulcerative colitis; tetracycline compds. with target therapeutic
 activities)
IT Blood vessel, disease
 (vascular stroke; tetracycline compds. with target therapeutic
 activities)
IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha., antagonists; tetracycline compds. with target therapeutic
 activities, and use with other agents)
IT 141907-41-7, Matrix metalloproteinase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MMP-4 and MMP5, inflammatory process-assocd. state assocd. with;
 tetracycline compds. with target therapeutic activities)

IT 10102-43-9, Nitric oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NO-assocd. state; tetracycline compds. with target therapeutic activities)

IT 56-86-0, L-Glutamic acid, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-glutamate therapy; tetracycline compds. with target therapeutic activities, and use with other agents)

IT 9001-12-1, Matrix metalloproteinase 1 9004-06-2, Matrix metalloproteinase 12 79955-99-0, Matrix metalloproteinase 3 140610-48-6, Matrix metalloproteinase 10 141256-52-2, Matrix metalloproteinase 7 145267-01-2, Matrix metalloproteinase 11 146480-35-5, Matrix metalloproteinase 2 146480-36-6, Matrix metalloproteinase 9 161384-17-4, Matrix metalloproteinase 14 172308-17-7, Matrix metalloproteinase 15 175449-82-8, Matrix metalloproteinase 13 182970-56-5, Matrix metalloproteinase 16 185766-51-2, Matrix metalloproteinase 20 188364-80-9, Matrix metalloproteinase 19 203810-08-6, Matrix metalloproteinase 17 252351-86-3, Matrix metalloproteinase 6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inflammatory process-assocd. state assocd. with; tetracycline compds. with target therapeutic activities)

IT 9001-08-5, Cholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; tetracycline compds. with target therapeutic activities, and use with other agents)

IT **389624-49-1P** 488820-35-5P 488820-36-6P 488820-38-8P 488820-39-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 127-33-3 564-25-0 914-00-1 2444-65-7 3242-03-3 4497-07-8 5874-95-3 5995-55-1 10118-89-5 16145-05-4 24290-70-8 31642-30-5 35689-63-5 35689-65-7 53108-41-1 53173-80-1 59046-79-6 77901-56-5 115207-75-5 120793-45-5 146253-71-6 146253-75-0 146278-01-5 146278-02-6 146278-03-7 149934-16-7 149934-19-0 151922-17-7 153621-68-2 161320-33-8 161321-34-2 161452-36-4 186759-47-7 186759-49-9 186759-51-3 186759-53-5 186759-55-7 186759-61-5 220620-09-7 233585-94-9 233585-95-0 233585-96-1 233585-97-2 233586-02-2 233586-03-3 233586-04-4 233586-06-6 233586-07-7 233586-08-8 233586-09-9 233586-10-2 233586-11-3 233586-12-4 233586-16-8 263760-96-9 263760-98-1 263761-01-9 263761-02-0 263761-08-6 295356-11-5 295356-12-6 295356-13-7 295356-16-0 295356-17-1 330627-21-9 330627-22-0 330627-23-1 330627-24-2 330627-26-4 330627-27-5 330627-32-2 344771-54-6 351336-92-0 351336-94-2 365276-98-8 365276-99-9 365277-00-5 365277-01-6 365277-02-7 365277-03-8 365277-04-9 365277-05-0 365277-06-1 365277-08-3 365277-11-8 365277-12-9 365277-13-0 365277-14-1 365277-16-3 365277-19-6 365277-20-9 365277-21-0 365277-22-1 365277-23-2 365277-24-3 365277-26-5 365277-28-7 365277-29-8 365277-34-5 365277-35-6 365277-36-7 365277-37-8 365277-38-9 365277-39-0 365277-40-3 365277-41-4 365277-42-5 365277-43-6 365277-44-7 365277-45-8 365277-46-9 365277-47-0 365277-48-1 365277-49-2 365277-50-5 365277-51-6 365277-52-7 365277-53-8 365277-54-9 365277-55-0 365277-56-1 365277-57-2 365277-58-3 365277-59-4 365277-60-7 365277-61-8 365277-62-9 365277-63-0 365277-64-1 365277-65-2 365277-66-3 365277-68-9 374748-06-8 380435-62-1 380435-63-2 380435-65-4 380435-76-7 380435-88-1 389081-55-4 389081-56-5 389081-58-7 389081-60-1 389081-61-2 389081-62-3 389081-63-4 389081-64-5 389081-65-6 389081-66-7 389081-67-8 389081-68-9 389081-69-0 389081-71-4 389081-72-5 389081-73-6

389081-74-7	389081-75-8	389081-76-9	389081-77-0	389081-78-1
389081-79-2	389081-80-5	389081-85-0	389139-10-0	389139-12-2
389139-15-5	389139-16-6	389139-17-7	389139-18-8	389139-19-9
389139-20-2	389139-21-3	389139-22-4	389139-23-5	389139-24-6
389139-25-7	389139-26-8	389139-27-9	389139-28-0	389139-29-1
389139-31-5	389139-32-6	389139-33-7	389139-34-8	389139-35-9
389139-36-0	389139-37-1	389139-38-2	389139-39-3	389139-40-6
389139-41-7	389139-42-8	389139-43-9	389139-44-0	389139-45-1
389139-46-2	389139-47-3	389139-48-4	389139-49-5	389139-51-9
389139-52-0	389139-53-1	389139-54-2	389139-55-3	389139-56-4
389139-57-5	389139-58-6	389139-59-7	389139-60-0	389139-61-1
389139-62-2	389139-63-3	389139-64-4	389139-65-5	389139-66-6
389139-67-7	389139-68-8	389139-69-9	389139-70-2	389139-71-3
389139-72-4	389139-73-5	389139-74-6	389139-75-7	389139-78-0
389139-79-1	389139-80-4	389139-81-5	389139-82-6	389139-83-7
389139-85-9	389139-86-0	389139-87-1	389139-88-2	389139-89-3
389139-90-6				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT	389139-91-7	389139-92-8	389139-93-9	389139-94-0	389139-95-1
	389139-96-2	389139-97-3	389139-98-4	389139-99-5	389140-00-5
	389140-01-6	389140-02-7	389140-03-8	389140-04-9	389140-06-1
	389570-43-8	389570-46-1	389570-49-4	389570-50-7	
	389570-51-8	389570-52-9	389570-53-0	389570-54-1	
	389623-72-7	389623-77-2	389623-80-7	389623-82-9	389623-86-3
	389623-88-5	389623-89-6	389623-91-0	389623-93-2	
	389623-95-4	389623-96-5	389623-97-6	389623-98-7	
	389623-99-8	389624-01-5	389624-02-6		
	389624-03-7	389624-04-8	389624-05-9	389624-08-2	
	389624-09-3	389624-12-8	389624-13-9	389624-14-0	
	389624-15-1	389624-18-4	389624-20-8		
	389624-21-9	389624-22-0	389624-23-1	389624-24-2	389624-26-4
	389624-27-5	389624-28-6	389624-29-7	389624-30-0	
	389624-31-1	389624-32-2	389624-33-3		
	389624-34-4	389624-35-5	389624-36-6		
	389624-37-7	389624-38-8	389624-39-9		
	389624-40-2	389624-41-3	389624-43-5		
	389624-44-6	389624-45-7	389624-46-8		
	389624-51-5	389624-52-6	389624-54-8	389624-55-9	
	389624-56-0	389624-57-1	389624-59-3	389624-62-8	
	389624-63-9	389624-66-2	389624-67-3		
	389624-68-4	389624-69-5	389624-70-8		
	389624-71-9	389624-72-0	389624-73-1		
	389624-75-3	389624-76-4	389624-77-5		
	389624-78-6	389624-79-7	389624-80-0		
	389624-81-1	389624-82-2	389624-83-3	389624-84-4	
	389624-85-5	389624-86-6	389624-87-7		
	389624-88-8	389624-89-9	389624-90-2	389624-91-3	
	389624-92-4	389624-93-5	389624-94-6	389624-95-7	
	389624-97-9	389624-98-0	389624-99-1	389625-00-7	389625-01-8
	389625-02-9	389625-03-0	389625-04-1	389625-05-2	389625-06-3
	389625-07-4	389625-07-4	389625-09-6	389625-09-6	389625-10-9
	389625-11-0	389625-12-1	439217-57-9	439217-59-1	459425-79-7
	459425-80-0	459425-96-8	459426-11-0	459809-42-8	459809-43-9
	459809-44-0	459809-45-1	459809-46-2	459809-47-3	
	459809-48-4	459809-49-5	459809-50-8	459809-51-9	
	459809-52-0	459809-53-1	459809-54-2	459809-55-3	
	459809-56-4	459809-57-5	459809-58-6	459809-59-7	
	459809-61-1	459809-63-3	459809-65-5		
	459809-66-6	459809-67-7	459809-68-8	459809-70-2	
	459809-72-4	459809-74-6	459809-76-8	459809-77-9	
	459809-79-1	459809-81-5	459809-82-6	459809-86-0	

459809-88-2 459809-91-7 **459809-92-8** 459809-93-9
459809-94-0 459809-95-1 459809-96-2 459809-97-3
 459809-98-4 459810-00-5 459810-01-6 459810-02-7 **459810-03-8**
459810-04-9 **459810-06-1** 459810-07-2
459810-09-4 460068-26-2 460068-27-3 460068-29-5
 460068-30-8 460068-31-9 460068-33-1 460068-34-2 460068-35-3
 460068-36-4 460068-38-6 460068-39-7 460068-40-0 460068-41-1
 460068-43-3 460068-44-4 460068-45-5 460068-46-6 460068-47-7
 460068-48-8 460068-49-9 460068-50-2 460068-51-3 460068-52-4
 460068-53-5 460068-54-6 460068-55-7 460068-57-9 460068-58-0
 460068-59-1 460068-60-4 460068-63-7 460068-64-8 460068-65-9
 460068-66-0 460068-67-1 460068-68-2 460068-69-3 460068-70-6
 460068-71-7 460068-72-8 460068-73-9 460068-74-0 460068-75-1
 460068-76-2 460068-77-3 460068-78-4 460068-79-5 460068-80-8
 460068-81-9 460068-82-0 460068-83-1 **460068-84-2**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT 460068-85-3 460068-86-4 460068-87-5 460068-88-6 460068-90-0
 460068-92-2 460068-93-3 460068-94-4 460068-95-5 460068-96-6
 460068-97-7 460068-99-9 460069-34-5 460069-38-9 460069-65-2
 460069-70-9 **460069-89-0** 460069-96-9 460070-02-4
 460070-03-5 460070-53-5 460070-61-5 460070-66-0 460070-73-9
 460070-76-2 460070-79-5 **460070-92-2** 460070-95-5
 460071-02-7 460071-04-9 460071-06-1 460071-09-4 460071-12-9
 460071-14-1 460071-17-4 460071-19-6 460071-29-8 460071-31-2
 460071-33-4 460071-37-8 460071-66-3 460071-69-6 460071-80-1
 460071-83-4 460071-83-4 460071-87-8 460071-89-0 460071-91-4
 460071-93-6 460071-97-0 460071-99-2 460072-01-9 460072-03-1
 460072-05-3 460072-07-5 460072-09-7 460072-10-0 460072-12-2
 460072-15-5 460072-17-7 460072-19-9 460072-21-3 460072-25-7
 460072-28-0 460072-29-1 460072-30-4 460072-31-5 460072-33-7
 460072-36-0 460072-38-2 460072-40-6 460072-43-9 460072-45-1
 460072-47-3 460072-49-5 460072-61-1 460072-63-3 460072-65-5
 460072-70-2 460072-73-5 460072-75-7 460072-78-0 460072-82-6
 460072-86-0 460072-89-3 460072-91-7 460072-93-9 460072-99-5
 460073-01-2 460073-03-4 460073-05-6 460073-07-8 460073-09-0
 460073-11-4 460073-15-8 460073-17-0 460073-21-6 460073-22-7
 460073-23-8 460073-25-0 460073-27-2 **460073-29-4**
460073-31-8 460073-33-0 460073-35-2 460073-37-4
 460073-40-9 460073-41-0 460073-43-2 460073-45-4 460073-47-6
 460073-49-8 460073-51-2 460073-55-6 460073-58-9 460073-60-3
 460073-62-5 460073-64-7 **460073-68-1** 460073-70-5
 460073-72-7 460073-74-9 460073-76-1 460073-78-3 460073-80-7
 460073-82-9 460073-84-1 460073-86-3 460073-88-5 460073-90-9
 460073-92-1 460073-94-3 460073-96-5 460074-00-4 460074-02-6
 460074-04-8 460074-06-0 460074-09-3 460074-11-7 460074-13-9
 460074-17-3 460074-19-5 460074-21-9 460074-23-1 460074-26-4
 460074-28-6 460074-30-0 460074-32-2 460074-34-4 460074-36-6
 460074-38-8 460074-40-2 460074-42-4 460074-44-6 460074-46-8
 460074-48-0 460074-50-4 460074-52-6 460074-54-8 460074-56-0
 460074-58-2 460074-60-6 460074-62-8 460074-64-0 460074-66-2
 460074-68-4 460074-69-5 460074-71-9 460074-73-1 460074-75-3
 460074-77-5 460074-79-7 460074-81-1 460074-85-5 460074-87-7
 460074-89-9 460074-91-3 460074-93-5 460074-95-7 460074-97-9
 460074-99-1 460075-04-1 460075-06-3 460075-08-5 460075-12-1
 460075-14-3 460075-62-1 460076-23-7 460082-87-5 460082-89-7
 460082-90-0 473973-13-6 473973-20-5 473973-34-1 473973-37-4
473973-41-0 473973-62-5 473973-64-7 473973-86-3 473973-96-
 5 473974-12-8 473974-75-3 473974-76-4 473974-77-5 473974-79-7
 473974-80-0 473974-81-1 473974-82-2 473974-83-3 473974-84-4
 473974-85-5 **488815-44-7** **488815-45-8**
488815-46-9 **488815-47-0** **488815-48-1**

488815-49-2 488815-52-7 488815-53-8 488815-54-9
 488815-55-0 488815-56-1 488815-57-2 488815-58-3 **488815-59-4**
488815-60-7 488815-61-8 488815-62-9 488815-63-0
 488815-64-1 488815-65-2 488815-66-3 488815-67-4 488815-68-5
 488815-69-6 488815-70-9 488815-71-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT 488815-72-1 488815-73-2 488815-74-3 488815-75-4 488815-76-5
 488815-77-6 488815-78-7 488815-79-8 488815-80-1 488815-82-3
 488815-89-0 488815-93-6 488815-98-1 488816-00-8 488816-09-7
 488816-13-3 488816-16-6 488816-18-8 488816-19-9 488816-26-8
 488816-37-1 488816-39-3 488816-42-8 488816-54-2 488816-55-3
 488816-58-6 488816-59-7 488816-64-4 488816-65-5 488816-70-2
 488816-71-3 488816-73-5 488816-75-7 488816-82-6 488816-86-0
 488816-88-2 488816-92-8 **488816-93-9** 488816-98-4
 488817-01-2 488817-06-7 488817-11-4 488817-13-6 488817-14-7
 488817-15-8 488817-16-9 488817-17-0 488817-18-1 488817-19-2
 488817-20-5 488817-21-6 488817-22-7 488817-23-8 488817-24-9
488817-25-0 488817-26-1 488817-27-2 488817-28-3
 488817-29-4 488817-30-7 488817-31-8 488817-32-9 488817-33-0
 488817-34-1 488817-35-2 488817-36-3 488817-37-4 488817-38-5
 488817-39-6 488817-40-9 488817-41-0 488817-42-1 488817-43-2
 488817-44-3 488817-45-4 488817-46-5 488817-47-6 488817-48-7
 488817-49-8 488817-50-1 **488817-51-2 488817-52-3**
 488817-53-4 488817-54-5 **488817-55-6 488817-56-7**
 488817-57-8 488817-58-9 **488817-59-0 488817-60-3**
 488817-61-4 **488817-62-5 488817-63-6** 488817-64-7
488817-65-8 488817-66-9 488817-67-0
488817-68-1 488817-69-2 488817-70-5
488817-71-6 488817-72-7 488817-73-8 488817-74-9
488817-75-0 488817-76-1 488817-77-2 488817-78-3
 488817-79-4 **488817-80-7** 488817-81-8 488817-82-9
 488817-89-6 488817-91-0 488817-92-1 488817-93-2 **488817-94-3**
 488817-95-4 488817-96-5 488817-97-6 488817-98-7 488817-99-8
 488818-00-4 488818-01-5 488818-02-6 488818-03-7 488818-04-8
 488818-05-9 488818-06-0 488818-07-1 488818-08-2 488818-09-3
 488818-10-6 488818-11-7 **488818-12-8** 488818-13-9
488818-14-0 488818-15-1 488818-16-2 488818-17-3
 488818-18-4 488818-19-5 488818-20-8 488818-21-9 488818-22-0
 488818-23-1 488818-24-2 **488818-25-3** 488818-26-4
 488818-27-5 **488818-28-6** 488818-29-7 **488818-30-0**
 488818-31-1 488818-32-2 488818-33-3 488818-34-4 488818-35-5
 488818-36-6 488818-37-7 488818-38-8 488818-39-9 488818-40-2
 488818-41-3 488818-42-4 488818-43-5 488818-44-6 488818-45-7
 488818-46-8 488818-47-9 488818-48-0 488818-49-1 488818-50-4
 488818-51-5 488818-52-6 488818-53-7 488818-54-8 488818-55-9
 488818-56-0 488818-57-1 488818-58-2 488818-59-3 488818-60-6
 488818-61-7 488818-63-9 488818-64-0 488818-65-1 488818-66-2
 488818-67-3 488818-68-4 **488818-69-5** 488818-70-8
 488818-71-9 488818-72-0 488818-73-1 488818-74-2 488818-75-3
 488818-76-4 488818-77-5 488818-78-6 488818-79-7 488818-80-0
488818-81-1 488818-82-2 488818-83-3 488818-84-4
 488818-85-5 488818-86-6 488818-87-7 488818-88-8 488818-89-9
 488818-90-2 488818-91-3 488818-92-4 488818-93-5 488818-94-6
 488818-95-7 488818-96-8 488818-97-9 488818-98-0 488818-99-1
 488819-00-7 488819-01-8 488819-02-9 488819-03-0 488819-04-1
 488819-05-2 488819-06-3 488819-07-4 488819-08-5 **488819-14-3**
 488819-15-4 488819-16-5 488819-17-6 488819-18-7 488819-19-8
 488819-20-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT 488819-21-2 488819-22-3 488819-23-4 488819-24-5 488819-25-6
 488819-26-7 488819-27-8 488819-28-9 488819-29-0 488819-30-3
 488819-31-4 488819-32-5 488819-33-6 488819-34-7 488819-35-8
 488819-36-9 488819-37-0 488819-38-1 488819-39-2 488819-40-5
 488819-41-6 488819-42-7 488819-43-8 488819-44-9 488819-45-0
 488819-46-1 488819-47-2 488819-48-3 488819-49-4 488819-50-7
 488819-51-8 488819-52-9 488819-53-0 488819-54-1 488819-55-2
 488819-56-3 488819-57-4 488819-58-5 488819-59-6 488819-60-9
 488819-61-0 488819-62-1 488819-63-2 488819-64-3 488819-65-4
 488819-66-5 488819-67-6 488819-68-7 488819-69-8 488819-70-1
 488819-71-2 488819-72-3 488819-73-4 488819-74-5 488819-75-6
 488819-76-7 488819-77-8 488819-78-9 488819-79-0 488819-80-3
 488819-81-4 488819-82-5 488819-83-6 488819-84-7 488819-85-8
 488819-86-9 488819-87-0 488819-88-1 **488819-89-2**
488819-90-5 488819-91-6 488819-92-7 488819-93-8
 488819-94-9 488819-95-0 **488819-96-1 488819-97-2**
 488819-98-3 488819-99-4 488820-00-4 488820-01-5 488820-02-6
 488820-03-7 488820-04-8 488820-05-9 488820-06-0 488820-07-1
 488820-08-2 488820-09-3 488820-10-6 488820-11-7 488820-12-8
 488820-13-9 488820-14-0 488820-15-1 488820-16-2 **488820-17-3**
488820-18-4 488820-19-5 **488820-20-8**
488820-21-9 488820-22-0 488820-23-1 488820-24-2
 488820-25-3 488820-26-4 488820-27-5 488820-28-6 **488820-29-7**
 488820-30-0 **488820-31-1** 488820-32-2 488820-33-3
 488820-34-4 488820-42-4 **488820-43-5** 488820-45-7
488820-46-8 488820-47-9 488820-48-0 488820-49-1
 488820-50-4 488821-84-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities)

IT 74-99-7, Propyne 100-39-0, Benzyl bromide 103-55-9 111-30-8,
 Glutaraldehyde 122-78-1, Phenylacetaldehyde 622-77-5, Benzylcyanamide
 808-26-4, Sancycline 871-84-1, 1,7-Octadiyne 5371-49-3 13614-98-7,
 Minocycline hydrochloride 25154-38-5, Piperazineethanol 25267-27-0,
 Iodobutane 50696-61-2, Cyclohexenylacetylene 55552-70-0, 3-Furanyl
 boronic acid 107099-99-0, 2,5-Dimethoxyphenyl boronic acid
 128796-39-4, 4-Trifluoromethylphenyl boronic acid 144025-03-6,
 2,4-Difluorophenyl boronic acid 149104-90-5, 4-Acetylphenylboronic acid
 389625-14-3 460076-35-1 460076-38-4 488820-37-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(tetracycline compds. with target therapeutic activities)

IT 113164-67-3P, 7-Iodosancycline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(tetracycline compds. with target therapeutic activities)

IT 50-81-7, Vitamin C, biological studies 53-03-2, Prednisone 302-79-4,
 Retinoic acid 303-98-0, Coenzyme Q10 987-78-0, CDP-choline
 1134-47-0, Baclofen 1406-18-4, Vitamin E 1744-22-5, Riluzole
 2763-96-4, Muscimol 7782-49-2, Selenium, biological studies
 10118-90-8, Minocycline 11096-26-7, Erythropoietin 11103-57-4, Vitamin
 A 14611-51-9, Selegiline 57828-26-9, Lipoic acid 60142-96-3,
 Gabapentin 84057-84-1, Lamotrigine 112924-45-5, Dexanabinol
 128298-28-2, Remacemide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(tetracycline compds. with target therapeutic activities, and use with
 other agents)

IT **389624-49-1P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(tetracycline compds. with target therapeutic activities)

RN 389624-49-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[2-(4-methylphenyl)ethyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:832571 HCAPLUS

DN 137:333118

TI Substituted tetracycline compounds for the treatment of malaria

IN Draper, Michael; Nelson, Mark L.; Frechette, Roger

PA Paratek Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-5 (Pharmacology)

Section cross-reference(s): 25, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	20021031	WO 2002-US12935	20020424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-286193P P 20010424

OS MARPAT 137:333118

AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amt. of a substituted tetracycline compd., such that malaria is treated or prevented. In one aspect, the invention provides pharmaceutical compns. which include an effective amt. of a tetracycline compd. to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used in combination with one or more antimalarial compds. or can be used to treat or prevent malaria

which is resistant to one or more other antimalarial compds. Compd. prepn. is described.

- ST tetracycline deriv prepn antimalarial; malaria treatment tetracycline deriv
- IT Antimalarials
Drug resistance
Malaria
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
(Substituted tetracycline compds. for the treatment of malaria)
- IT Sulfonamides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Substituted tetracycline compds. for the treatment of malaria)
- IT Headache
(and malaise, supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
- IT Antimicrobial agents
(antimicrobial Gram-pos. activity; Substituted tetracycline compds. for the treatment of malaria)
- IT Drug delivery systems
(prodrugs; Substituted tetracycline compds. for the treatment of malaria)
- IT Spleen, disease
(splenomegaly, supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
- IT Anemia (disease)
Fever and Hyperthermia
(supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
- IT Antipyretics
(supplementary compd.; Substituted tetracycline compds. for the treatment of malaria)
- IT Drug delivery systems
(tetracycline derivs. for malaria treatment)
- IT 58-14-0, Pyrimethamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Substituted tetracycline compds. for the treatment of malaria)
- IT 54-05-7, Chloroquine 56-54-2, Quinidine 86-42-0, Amodiaquine 90-34-6, Primaquine 130-95-0, Quinine 500-92-5, Proguanil 537-21-3, Chlorproguanil 550-81-2, Amopyroquine 738-70-5, Trimethoprim 37338-39-9 37357-69-0 53230-10-7, Mefloquine 63968-64-9, Artemisinin 69756-53-2, Halofantrine 71963-77-4, Artemether 74847-35-1, Pyronaridine 82186-77-4, Lumefantrine 88495-63-0, Artesunate 95233-18-4, Atovaquone 123407-36-3, Arteflene
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)
- IT 389139-31-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)
- IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0 808-26-4 914-00-1 10118-90-8 31642-30-5 35689-65-7 146253-75-0 146278-03-7 151922-17-7 186759-47-7 186759-51-3 186759-53-5 201849-42-5 233585-95-0 233586-04-4 233586-06-6 233586-09-9 263760-98-1 263761-02-0 263761-08-6 330627-24-2 344771-54-6 351336-94-2 365277-01-6 365277-22-1 365277-23-2 365277-28-7 365277-29-8 365277-38-9 365277-45-8 365277-47-0 365277-51-6 365277-55-0 365277-56-1 365277-57-2 365277-59-4 365277-60-7 365277-63-0 365277-66-3 374748-06-8 380435-62-1 380435-63-2

380435-65-4 380435-76-7 389081-56-5 389081-58-7 389081-61-2
 389081-62-3 389081-64-5 389081-77-0 389081-85-0 389139-10-0
 389139-12-2 389139-16-6 389139-19-9 389139-20-2 389139-21-3
 389139-22-4 389139-23-5 389139-24-6 389139-27-9 389139-28-0
 389139-30-4 389139-33-7 389139-41-7 389139-43-9 389139-44-0
 389139-45-1 389139-46-2 389139-48-4 389139-49-5 389139-50-8
 389139-51-9 389139-52-0 389139-53-1 389139-54-2 389139-55-3
 389139-58-6 389139-62-2 389139-63-3 389139-64-4 389139-65-5
 389139-67-7 389139-68-8 389139-78-0 389139-81-5 389139-86-0
 389139-91-7 389139-93-9 389140-00-5 389623-72-7 389623-77-2
 389623-80-7 389623-82-9 389623-88-5 **389623-89-6**
389623-90-9 **389623-91-0** 389623-93-2 389623-95-4
 389623-96-5 389623-97-6 **389623-99-8** **389624-00-4**
389624-01-5 **389624-02-6** 389624-03-7 389624-04-8
 389624-05-9 **389624-06-0** 389624-07-1 **389624-08-2**
389624-09-3 **389624-10-6** **389624-11-7**
 389624-12-8 **389624-14-0** **389624-15-1**
389624-16-2 **389624-18-4** **389624-19-5**
389624-20-8 389624-21-9 389624-22-0 389624-23-1
 389624-24-2 **389624-26-4** **389624-27-5** 389624-28-6
389624-30-0 **389624-32-2** **389624-33-3**
389624-35-5 **389624-36-6** **389624-37-7**
389624-38-8 **389624-39-9** **389624-40-2**
389624-41-3 **389624-42-4** **389624-43-5**
389624-51-5 389624-55-9 **389624-62-8**
389624-73-1 **389624-74-2** **389624-75-3**
 389624-81-1 **389624-83-3** **389624-85-5**
389624-95-7 **389624-96-8** 389624-97-9 389624-99-1
 459809-44-0 **459809-46-2** 459809-53-1 **459809-67-7**
459809-72-4 **459809-99-5** 459810-00-5
459810-03-8 **459810-06-1** 460068-29-5 460068-31-9
 460068-32-0 460068-33-1 460068-36-4 460068-38-6 460068-42-2
 460068-44-4 460068-45-5 460068-48-8 460068-51-3 460068-55-7
 460068-57-9 460068-58-0 460068-59-1 460068-60-4 460068-62-6
 460068-65-9 460068-66-0 460068-68-2 460068-76-2 460068-77-3
 460068-78-4 460068-80-8 460068-86-4 460068-87-5 460068-93-3
 460068-95-5 460068-96-6 460068-97-7 460069-34-5 460069-38-9
 460069-65-2 460069-70-9 460069-96-9 460070-02-4 460070-03-5
 460070-61-5 460070-66-0 460070-73-9 460070-95-5 460071-09-4
 460071-12-9 460071-14-1 460071-33-4 460072-33-7 460072-47-3
 460072-59-7 460072-65-5 460073-05-6 460073-17-0 460073-22-7
 460074-06-0 460074-13-9 460074-19-5 460074-21-9 460075-62-1
 460082-77-3 460082-89-7 473972-91-7 473973-13-6 473973-20-5
 473973-34-1 473973-37-4 **473973-41-0** 473973-62-5
 473973-64-7 473973-69-2 473973-86-3 473973-96-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(Substituted tetracycline compds. for the treatment of malaria)

IT 473974-12-8 473974-75-3 473974-76-4 473974-77-5 473974-79-7
 473974-80-0 473974-81-1 473974-82-2 473974-83-3 473974-84-4
 473974-85-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(Substituted tetracycline compds. for the treatment of malaria)

IT 263760-96-9P, 7-Phenylsancycline 263760-99-2P 389140-02-7P
 389623-67-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(tetracycline derivs. for malaria treatment)

IT 98-80-6, Phenylboronic acid 1679-18-1; 4-Chlorophenylboronic acid
 1765-93-1, 4-Fluorophenylboronic acid 14047-29-1, p-Carboxyphenylboronic
 acid 35037-73-1, 4-Trifluoromethoxyphenylisocyanate 59046-78-5

263761-01-9 389140-05-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(tetracycline derivs. for malaria treatment)

IT 113164-67-3P, 7-Iodosancycline 389140-04-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(tetracycline derivs. for malaria treatment)


IT 389623-89-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

RN 389623-89-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 7-(cyclohexylethynyl)-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:716234 HCAPLUS

DN 137:247552

TI Preparation of 7, 9-substituted tetracycline derivatives for
pharmaceutical use as antibacterial agentsIN Nelson, Mark L.; Frechette, Roger; Viski,
Peter; Ismail, Mohamed; Bowser, Todd;
McIntyre, Laura; Bhatia, Beena; Hawkins, Paul;
Reddy, Laxma; Stapleton, Karen; Warchol, Tad; Sheahan,
Paul

PA Paratek Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C237-26

ICS A61K031-65

CC 26-6 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1, 10, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072532	A1	20020919	WO 2001-US20722	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				


RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002193354 A1 20021219 US 2001-895797 20010629

PRAI US 2001-275620P P 20010313

OS MARPAT 137:247552

GI



AB 7,9-Substituted tetracycline derivs., such as I [X = CHC(R13Y'Y), CR6'R6, S, NR6, O; R2, R2', R4', R4" = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroarom., prodrug; R4 = NR4'R4", alkyl, alkenyl, alkynyl, OH, halogen, H; R2', R3, R10, R11, R12 = H, prodrug; R5 = OH, H, thiol, alkanoyl, aroyl, aryl, alkoxy, alkylthio, carbonyloxy; R6, R6' = H, methylene, absent, OH, halogen, thiol, alkyl, alkenyl, alkynyl, alkoxy; R7 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, arylalkyl, arylalkenyl, arylalkynyl, aminoalkyl; R8 = H, OH, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R9 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy; R13 = H, OH, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; Y, Y' = H, halogen, OH, CN, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino], and pharmaceutically acceptable salts thereof, were prepd. to treat numerous tetracycline compd.-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline compds. in general, such as blocking tetracycline efflux and modulation of gene expression. Thus, reaction between N-iodosuccinimide and sancycline hydrochloride hemihydrate yielded 7,9-diiodosancycline II (R = I) which was reacted with 3,4-methylenedioxyphenyl boronic acid to afford 7,9-bis(3,4-methylenedioxyphenyl)-sancycline II (R = 3,4-methylenedioxyphenyl). The prepd. tetracycline derivs. were tested for antibacterial activity against Staphylococcus aureus, Enterococcus hirae and Escherichia coli.

ST tetracycline deriv prepn antibacterial; sancycline deriv prepn antibacterial

IT Infection

(bacterial, treatment; prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT Human

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT Tetracyclines

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT Escherichia coli
(prepn. of 7, 9-substituted tetracycline derivs. for treating bacterial infection assocd. with E. coli)

IT Enterococcus faecalis
(prepn. of 7, 9-substituted tetracycline derivs. for treating bacterial infection assocd. with E. faecalis)

IT Enterococcus hirae
(prepn. of 7, 9-substituted tetracycline derivs. for treating bacterial infection assocd. with E. hirae)

IT Staphylococcus aureus
(prepn. of 7, 9-substituted tetracycline derivs. for treating bacterial infection assocd. with S. aureus)

IT **459810-04-9P** 459810-08-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 330627-26-4P 459809-42-8P **459809-43-9P** 459809-44-0P
459809-45-1P **459809-46-2P** **459809-47-3P**
459809-48-4P 459809-49-5P 459809-50-8P **459809-51-9P**
459809-52-0P 459809-53-1P **459809-54-2P** 459809-55-3P
459809-56-4P 459809-57-5P **459809-58-6P** 459809-59-7P
459809-61-1P **459809-63-3P** **459809-65-5P**
459809-66-6P **459809-67-7P** 459809-68-8P **459809-70-2P**
459809-72-4P 459809-74-6P 459809-76-8P 459809-77-9P
459809-79-1P **459809-81-5P** 459809-82-6P 459809-84-8P
459809-86-0P 459809-88-2P 459809-91-7P **459809-92-8P**
459809-93-9P **459809-94-0P** 459809-95-1P 459809-96-2P
459809-97-3P 459809-98-4P **459809-99-5P** 459810-00-5P
459810-01-6P 459810-02-7P **459810-03-8P** **459810-05-0P**
459810-06-1P 459810-07-2P **459810-09-4P** 459810-11-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 516-12-1, N-Iodosuccinimide 808-26-4, Sancycline 1066-54-2,
Trimethylsilyl acetylene 50696-61-2, Cyclohexenyl-acetylene 53173-80-1
94839-07-3, 3,4-Methylenedioxyphenyl boronic acid 389625-14-3
459810-12-9 460091-55-8, Sancycline hydrochloride hemihydrate
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 113164-67-3P, 7-Iodosancycline **263761-05-3P**, 7-Ethynylsancycline
263761-08-6P, 7,9-Diiodosancycline **389624-14-0P**,
7-Ethylsancycline **459810-10-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ashley, R; WO 0028983 A 2000 HCAPLUS
(2) Farmaceutici Italia; DE 2346535 A 1974 HCAPLUS
(3) Farmaceutici Italia; DE 2527568 A 1976 HCAPLUS
(4) James, H; US 3338963 A 1967 HCAPLUS
(5) Winterbottom, R; US 3433834 A 1969 HCAPLUS


IT **459810-04-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 7, 9-substituted tetracycline derivs. for pharmaceutical use

as antibacterial agents)

RN 459810-04-9 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-iodo-1,11-dioxo-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:716035 HCAPLUS

DN 137:244598

TI Substituted tetracycline compounds as synergistic antifungal agents

IN Draper, Michael; **Nelson, Mark L.**

PA Paratek Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 1, 5, 26

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072031	A2	20020919	WO 2002-US7829	20020314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-275899P P 20010314

OS MARPAT 137:244598

AB Methods and compns. for treating for the synergistic treatment of fungal assocd. disorders are discussed. The method includes administering the antifungal agent with an effective amt. of a substituted tetracycline compd., such that the antifungal activity of the antifungal agent is increased. Examples of antifungal agents include polyenes such as amphotericin B.

ST tetracycline synergistic antifungal agent

IT Actinomyces

(actinomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Aspergillus

(aspergillosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Blastomyces

Mycosis

- (blastomycosis, North American; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Blastomyces
Mycosis
(blastomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Candida albicans
(candidiasis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Drug delivery systems
(carriers; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Skin, disease
(chromoblastomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Mycosis
(coccidioidomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Tinea (skin disease)
(cruris; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Cryptococcus neoformans
(cryptococcosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Lymphatic system
(disease, epizootic lymphangitis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Toxicity
(drug, immunosuppression from, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Entomophthorales
(entomophthoromycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Histoplasma farciminosum
(epizootic lymphangitis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Immunosuppression
(from chemotherapy, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT AIDS (disease)
Immunodeficiency
(fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Disease, plant
(fungal; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Geotrichum candidum
(geotrichosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Chemotherapy
(immunosuppression from, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Histoplasma capsulatum
(infection with; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Skin-infecting fungi
(infections from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Mucor
(mucormycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Mycosis

- (mycetoma; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Oomycetes
(oomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Paecilomyces
(paecilimycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Paracoccidioides brasiliensis
(paracoccidioidomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Penicillium
(penicilliosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Rhinosporidium
(rhinosporidiosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Aspergillus nidulans
Athlete's foot
Candida albicans
Candida dubliniensis
Candida glabrata
Candida guilliermondii
Candida krusei
Candida lusitaniae
Candida neoformans
Candida parapsilosis
Candida tropicalis
Cytotoxicity
Human
Issatchenkia orientalis
Mammalia
Mycosis
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Polyenes
Tetracyclines
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Drug interactions
Fungicides
(synergistic; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT Anti-inflammatory agents
(tetracyclines; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT **389624-44-6P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
- IT **263761-05-3P** 351336-94-2P 380435-63-2P 389623-77-2P
389624-48-0P 389624-49-1P 389624-67-3P
389624-88-8P 460068-27-3P 460069-92-5P 460072-21-3P
460073-05-6P 460073-43-2P 460073-62-5P **460073-68-1P**
460073-82-9P 460074-13-9P 460074-36-6P 460074-56-0P 460074-58-2P
460074-69-5P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in
relation to cytotoxicity)

IT 564-25-0 1397-89-3, Amphotericin B 5995-55-1 31642-30-5 35689-65-7
113164-67-3 120793-45-5 146253-75-0 146278-03-7 151922-17-7
161321-34-2 161452-36-4 186759-47-7 186759-51-3 186759-53-5
186759-61-5 220620-09-7 233585-94-9 233585-95-0 233586-04-4
233586-06-6 233586-11-3 233586-12-4 263760-96-9 263760-99-2
263761-02-0 263761-08-6 295356-11-5 295356-12-6 330627-21-9
330627-24-2 330627-27-5 365277-01-6 365277-03-8 365277-07-2
365277-13-0 365277-14-1 365277-16-3 365277-23-2 365277-28-7
365277-29-8 365277-35-6 365277-36-7 365277-38-9 365277-39-0
365277-40-3 365277-42-5 365277-43-6 365277-46-9 365277-47-0
365277-48-1 365277-49-2 365277-50-5 365277-51-6 365277-52-7
365277-53-8 365277-54-9 365277-55-0 365277-56-1 365277-60-7
365277-61-8 365277-62-9 365277-63-0 365277-65-2 374748-06-8
380435-65-4 380435-74-5 380435-76-7 389081-56-5 389081-58-7
389081-59-8 389081-61-2 389081-63-4 389081-67-8 389081-68-9
389081-77-0 389081-78-1 389081-82-7 389081-85-0 389139-10-0
389139-12-2 389139-16-6 389139-17-7 389139-19-9 389139-20-2
389139-21-3 389139-22-4 389139-23-5 389139-24-6 389139-26-8
389139-27-9 389139-28-0 389139-31-5 389139-32-6 389139-33-7
389139-41-7 389139-43-9 389139-45-1 389139-46-2 389139-48-4
389139-49-5 389139-50-8 389139-51-9 389139-53-1 389139-54-2
389139-55-3 389139-56-4 389139-58-6 389139-59-7 389139-61-1
389139-62-2 389139-63-3 389139-64-4 389139-65-5 389139-66-6
389139-67-7 389139-68-8 389139-69-9 389139-70-2 389139-71-3
389139-72-4 389139-73-5 389139-75-7 389139-76-8 389139-78-0
389139-79-1 389139-81-5 389139-82-6 389139-83-7 389139-85-9
389139-86-0 389139-87-1 389139-88-2 389139-89-3 389139-90-6
389139-91-7 389139-92-8 389139-93-9 389139-94-0 389139-95-1
389139-96-2 389139-97-3 389139-98-4 389139-99-5 389140-00-5
389140-01-6 389140-02-7 389140-03-8 389570-51-8 389623-72-7
389623-82-9 389623-84-1 389623-86-3 389623-88-5
389623-89-6 389623-90-9 389623-91-0
389623-95-4 389623-97-6 389623-99-8 389624-05-9
389624-06-0 389624-08-2 389624-09-3
389624-13-9 389624-14-0 389624-18-4
389624-19-5 389624-20-8 389624-21-9 389624-22-0
389624-24-2 389624-31-1 389624-32-2
389624-33-3 389624-34-4 389624-36-6
389624-38-8 389624-39-9 389624-40-2
389624-41-3 389624-42-4 389624-43-5
389624-47-9 389624-51-5 389624-52-6
389624-53-7 389624-54-8 389624-55-9 389624-56-0
389624-57-1 389624-59-3 389624-60-6 389624-61-7
389624-64-0 389624-65-1 389624-66-2
389624-68-4 389624-69-5 389624-70-8
389624-71-9 389624-72-0 389624-73-1
389624-74-2 389624-75-3 389624-76-4
389624-77-5 389624-78-6 389624-79-7
389624-80-0 389624-81-1 389624-82-2 389624-83-3
389624-85-5 389624-86-6 389624-87-7
389624-89-9 389624-90-2 389624-91-3 389624-92-4
389624-93-5 389624-94-6 389624-97-9 389624-98-0 389624-99-1
389625-01-8 389625-02-9 389625-03-0 389625-04-1 389625-06-3
389625-07-4 389625-09-6 389625-09-6 389625-10-9 389625-11-0
389625-12-1

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in
relation to cytotoxicity)

IT 459809-44-0 459809-45-1 459809-46-2 459809-47-3

459809-48-4	459809-49-5	459809-50-8	459809-51-9	
459809-52-0	459809-53-1	459809-54-2	459809-55-3	
459809-56-4	459809-57-5	459809-61-1		
459809-63-3	459809-65-5	459809-66-6		
459809-67-7	459809-68-8	459809-70-2		
459809-72-4	459809-74-6	459809-76-8	459809-77-9	
459809-82-6	459809-88-2	459809-91-7	459809-93-9	459809-94-0
459809-95-1	459809-96-2	459809-97-3	459809-98-4	459809-99-5
459810-00-5	459810-01-6	459810-02-7	459810-04-9	
459810-07-2	459810-08-3	460068-26-2	460068-28-4	460068-29-5
460068-30-8	460068-31-9	460068-32-0	460068-33-1	460068-34-2
460068-35-3	460068-36-4	460068-37-5	460068-38-6	460068-39-7
460068-40-0	460068-41-1	460068-42-2	460068-43-3	460068-44-4
460068-45-5	460068-46-6	460068-47-7	460068-48-8	460068-49-9
460068-50-2	460068-51-3	460068-52-4	460068-53-5	460068-54-6
460068-55-7	460068-56-8	460068-57-9	460068-58-0	460068-59-1
460068-60-4	460068-61-5	460068-62-6	460068-63-7	460068-64-8
460068-65-9	460068-66-0	460068-67-1	460068-68-2	460068-69-3
460068-70-6	460068-71-7	460068-72-8	460068-73-9	460068-74-0
460068-75-1	460068-76-2	460068-77-3	460068-78-4	460068-79-5
460068-80-8	460068-81-9	460068-82-0	460068-83-1	460068-84-2
460068-85-3	460068-86-4	460068-87-5	460068-88-6	460068-89-7
460068-90-0	460068-91-1	460068-92-2	460068-93-3	460068-94-4
460068-95-5	460068-96-6	460068-97-7	460068-99-9	460069-25-4
460069-34-5	460069-38-9	460069-65-2	460069-70-9	460069-76-5
460069-89-0	460069-96-9	460069-99-2	460070-02-4	
460070-03-5	460070-34-2	460070-44-4	460070-53-5	460070-61-5
460070-66-0	460070-73-9	460070-76-2	460070-79-5	460070-83-1
460070-92-2	460070-95-5	460071-02-7	460071-04-9	
460071-06-1	460071-09-4	460071-12-9	460071-14-1	460071-17-4
460071-19-6	460071-23-2	460071-29-8	460071-31-2	460071-33-4
460071-37-8	460071-66-3	460071-69-6	460071-80-1	460071-83-4
460071-87-8	460071-89-0	460071-91-4	460071-93-6	460071-95-8
460071-97-0	460071-99-2	460072-01-9	460072-03-1	460072-05-3
460072-07-5	460072-09-7	460072-10-0	460072-12-2	460072-15-5
460072-17-7	460072-19-9	460072-25-7	460072-27-9	460072-28-0
460072-29-1	460072-30-4	460072-31-5	460072-33-7	460072-36-0
460072-38-2	460072-40-6	460072-43-9	460072-45-1	460072-47-3
460072-49-5	460072-51-9	460072-53-1	460072-55-3	460072-57-5
460072-59-7	460072-61-1	460072-63-3	460072-65-5	460072-68-8
460072-70-2	460072-73-5	460072-75-7	460072-78-0	460072-80-4
460072-82-6	460072-86-0	460072-89-3	460072-91-7	460072-93-9
460072-99-5	460073-01-2	460073-03-4	460073-07-8	460073-09-0
460073-11-4	460073-15-8	460073-17-0	460073-21-6	460073-22-7
460073-23-8	460073-25-0	460073-27-2	460073-29-4	
460073-31-8	460073-33-0	460073-35-2	460073-37-4	
460073-40-9	460073-41-0	460073-45-4	460073-47-6	460073-49-8
460073-51-2	460073-53-4	460073-55-6	460073-58-9	460073-60-3
460073-64-7	460073-66-9	460073-70-5	460073-72-7	
460073-74-9	460073-76-1			

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT	460073-78-3	460073-80-7	460073-84-1	460073-86-3	460073-88-5
	460073-90-9	460073-92-1	460073-94-3	460073-96-5	460073-98-7
	460074-00-4	460074-02-6	460074-04-8	460074-06-0	460074-09-3
	460074-11-7	460074-15-1	460074-17-3	460074-19-5	460074-21-9
	460074-23-1	460074-26-4	460074-28-6	460074-30-0	460074-32-2
	460074-34-4	460074-38-8	460074-40-2	460074-42-4	460074-44-6
	460074-46-8	460074-48-0	460074-50-4	460074-52-6	460074-54-8
	460074-60-6	460074-62-8	460074-64-0	460074-66-2	460074-68-4
	460074-71-9	460074-73-1	460074-75-3	460074-77-5	460074-79-7

460074-81-1 460074-83-3 460074-85-5 460074-87-7 460074-89-9
 460074-91-3 460074-93-5 460074-95-7 460074-97-9 460074-99-1
 460075-04-1 460075-06-3 460075-08-5 460075-10-9 460075-12-1
 460075-14-3 460075-62-1 460076-23-7 460082-61-5 460082-62-6

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 74-99-7, Propyne 78-84-2, Isobutyraldehyde 103-55-9,
 N'-Benzyl-N,N-dimethylethylenediamine 103-76-4, 1-Piperazineethanol
 111-30-8, Glutaraldehyde 122-78-1, Phenylacetaldehyde 622-77-5,
 Benzylcyanamide 808-26-4, Sancycline 871-84-1, 1,7-Octadiyne
 914-00-1, Methacycline 4199-35-3 27329-70-0, 2-Formylfuran-5-boronic
 acid 50696-61-2, Cyclohexenylacetylene 55552-70-0, 3-Furanylboronic
 acid 107099-99-0, 2,5-Dimethoxyphenylboronic acid 128796-39-4,
 4-Trifluoromethylphenylboronic acid 144025-03-6, 2,4-
 Difluorophenylboronic acid 149104-90-5 149934-19-0 380435-62-1
 389140-04-9 **459810-03-8** 460076-33-9 460076-36-2
 460076-37-3

RL: RCT (Reactant); RACT (Reactant or reagent)
 (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)


IT 460076-34-0P 460076-35-1P 460076-38-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT **389624-44-6P**
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

RN 389624-44-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
 3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1-propynyl)-, (4S,4aS,5aR,12aS)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2003 ACS
 AN 2002:716027 HCAPLUS
 DN 137:244597
 TI Substituted tetracycline compounds as antifungal agents
 IN Draper, Michael; Nelson, Mark L.
 PA Paratek Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

IC ICM A61K
 CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
 Section cross-reference(s): 1, 5, 26

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072022	A2	20020919	WO 2002-US7502	20020314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-275948P	P	20010314		
OS	MARPAT 137:244597				
AB	Methods and compns. for treating fungal assocd. disorders in subjects are discussed. The method includes contacting the fungus with an effective amt. of a substituted tetracycline compd., such that the growth of said fungus is inhibited.				
ST	tetracycline antifungal agent				
IT	Actinomycetes (actinomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Fungicides (agrochem.; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Aspergillus (aspergillosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Blastomycetes Mycosis (blastomycosis, North American; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Blastomycetes Mycosis (blastomycosis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Candida albicans (candidiasis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Drug delivery systems (carriers; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Skin, disease (chromoblastomycosis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Mycosis (coccidioidomycosis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Tinea (skin disease) (cruris; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Cryptococcus neoformans (cryptococcosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Lymphatic system (disease, epizootic lymphangitis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)				
IT	Toxicity (drug, immunosuppression from, fungal infections in; substituted				

- tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Entomophthorales
 - (entomophthoromycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Histoplasma farciminosum
 - (epizootic lymphangitis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Immunosuppression
 - (from chemotherapy, fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT AIDS (disease)
 - Immunodeficiency
 - (fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Disease, plant
 - (fungal; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Geotrichum candidum
 - (geotrichosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Chemotherapy
 - (immunosuppression from, fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Histoplasma capsulatum
 - (infection with; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Skin-infecting fungi
 - (infections from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Mucor
 - (mucormycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Mycosis
 - (mycetoma; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Oomycetes
 - (oomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Paecilomyces
 - (paecilimycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Paracoccidioides brasiliensis
 - (paracoccidioidomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Penicillium
 - (penicilliosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Rhinosporidium
 - (rhinosporidiosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
- IT Athlete's foot
 - Candida
 - Candida albicans
 - Candida dubliniensis
 - Candida glabrata
 - Candida guilliermondii
 - Candida krusei
 - Candida lusitaniae
 - Candida neoformans
 - Candida parapsilosis
 - Candida tropicalis
 - Cytotoxicity
 - Fungicides

Human
Mammalia
Mycosis

(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT Tetracyclines

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 460072-70-2

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(a substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 31642-30-5 113164-67-3 161452-36-4 233585-94-9 233585-95-0
233586-04-4 233586-06-6 233586-12-4 330627-29-7 351336-94-2
365277-14-1 365277-36-7 365277-88-9 380435-74-5 380435-76-7
389139-17-7 389139-27-9 389139-31-5 389139-33-7 389139-41-7
389139-43-9 389139-45-1 389139-49-5 389139-56-4 389139-64-4
389139-72-4 389139-73-5 389139-74-6 389139-75-7 389139-76-8
389139-80-4 389139-87-1 389139-90-6 389139-91-7 **389623-86-3**
389623-88-5 **389623-89-6** **389623-90-9** 389623-96-5
389623-99-8 **389624-06-0** **389624-08-2**
389624-09-3 389624-13-9 **389624-18-4**
389624-19-5 **389624-20-8** 389624-21-9
389624-33-3 **389624-36-6** **389624-38-8**
389624-39-9 **389624-41-3** **389624-42-4**
389624-43-5 **389624-48-0** **389624-64-0**
389624-65-1 **389624-67-3** **389624-75-3**
389624-76-4 **389624-77-5** **389624-78-6**
389624-96-8 389625-11-0 **459809-54-2** 459809-55-3
459809-63-3 **459809-81-5** **459809-94-0**
459809-99-5 **459810-05-0** 459810-08-3 460068-29-5
460068-30-8 460068-39-7 460068-40-0 460068-43-3 460068-44-4
460068-48-8 460068-49-9 460068-60-4 460068-72-8 460068-80-8
460068-84-2 460068-85-3 460068-86-4 460068-87-5
460068-88-6 460068-90-0 460069-34-5 460069-38-9 460071-97-0
460071-99-2 460072-10-0 460072-78-0 460072-80-4 **460073-29-4**
460073-37-4 **460073-68-1** 460074-28-6 460074-52-6
460074-60-6 460074-73-1 460082-75-1 460082-77-3 460082-81-9
460082-82-0 460082-83-1 460082-84-2 460082-85-3 **460082-86-4**
460082-87-5 460082-88-6 460082-89-7 460082-90-0 460082-91-1

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 693-02-7, 1-Hexyne 808-26-4, Sancycline 85199-06-0,
2,5-Dimethylphenylboronic acid 389139-46-2, 9-(4-
Fluorophenylethynyl)minocycline 389140-04-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 389139-70-2P, 9-(4'-Fluorophenylethyl)-Minocycline 460082-93-3P
460082-94-4P, 9-(2',5'-Dimethylphenyl)minocycline


RL: SPN (Synthetic preparation); PREP (Preparation)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT **389623-86-3**

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)


RN 389623-86-3 HCAPLUS
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(phenylethynyl)-, (4S,4aS,5aR,12aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2003 ACS
 AN 2002:51420 HCAPLUS
 DN 136:102232
 TI Preparation of 7-substituted tetracycline derivatives for pharmaceutical use as antibacterial agents
 IN Nelson, Mark L.; Frechette, Roger; Viski, Peter; Ismail, Mohamed; Bowser, Todd; Bhatia, Beena; Messersmith, David; McIntyre, Laura; Koza, Darrell; Rennie, Glen; Sheahan, Paul; Hawkins, Paul; Verma, Atul; Warchol, Tad; Bandarage, Upul
 PA Trustees of Tufts College, USA; Paratek Pharmaceuticals, Inc.
 SO PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C237-00
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 10
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004407	A2	20020117	WO 2001-US20766	20010629
	WO 2002004407	A3	20020404		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2003055025	A1	20030320	US 2001-895812	20010629
	EP 1301466	A2	20030416	EP 2001-950674	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-216760P	P	20000707		
	US 2001-275576P	P	20010313		
	WO 2001-US20766	W	20010629		
OS	MARPAT 136:102232				
GI					



AB 7-Substituted tetracycline derivs., such as I [R7 = NO₂, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, amino, arylalkenyl, arylalkynyl, aminoalkyl, etc.], were prepd. for therapeutic use as antibacterial agents. Thus, 7-phenylsancycline I (R7 = Ph) was prepd. in 42% yield by arom. coupling reaction of 7-iodosancycline I (R7 = iodo) with PhB(OH)₂ using Pd(OAc)₂ and Na₂CO₃ in MeOH under an argon atm. at r.t. for 2 h. The prepd. tetracycline derivs. were tested for antibacterial activity against *Escherichia coli*, *Enterococcus hirae*, and *Staphylococcus aureus*.

ST tetracycline deriv prepn antibacterial agent; sancycline deriv prepn antibacterial agent

IT Antibacterial agents

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 263761-01-9P 389624-24-2P **389624-36-6P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 263760-96-9P 263760-98-1P 263760-99-2P 263761-02-0P 365277-42-5P
 365277-44-7P 365277-45-8P 374748-06-8P 380435-62-1P 380435-63-2P
 380435-65-4P 380435-76-7P 389623-67-0P 389623-72-7P 389623-74-9P
 389623-77-2P 389623-80-7P 389623-82-9P **389623-84-1P**
389623-86-3P 389623-88-5P **389623-89-6P**
389623-90-9P **389623-91-0P** 389623-93-2P 389623-95-4P
 389623-96-5P 389623-97-6P **389623-98-7P** **389623-99-8P**
389624-00-4P **389624-01-5P** **389624-02-6P**
 389624-03-7P 389624-04-8P 389624-05-9P **389624-06-0P**
 389624-07-1P **389624-08-2P** **389624-09-3P**
389624-10-6P **389624-11-7P** 389624-12-8P 389624-13-9P
389624-14-0P **389624-15-1P** **389624-16-2P**
389624-17-3P **389624-18-4P** **389624-19-5P**
389624-20-8P 389624-21-9P 389624-22-0P 389624-23-1P
389624-25-3P **389624-26-4P** **389624-27-5P**
 389624-28-6P 389624-29-7P **389624-30-0P** **389624-31-1P**
389624-32-2P **389624-33-3P** 389624-34-4P
389624-35-5P **389624-37-7P** **389624-38-8P**
389624-39-9P **389624-40-2P** **389624-41-3P**
389624-42-4P **389624-43-5P** **389624-44-6P**
 389624-45-7P **389624-46-8P** **389624-47-9P**
389624-48-0P **389624-49-1P** **389624-50-4P**
389624-51-5P **389624-52-6P** **389624-53-7P**
 389624-54-8P 389624-55-9P **389624-56-0P** 389624-57-1P
 389624-58-2P 389624-59-3P **389624-60-6P** **389624-61-7P**
389624-62-8P **389624-63-9P** **389624-64-0P**
389624-65-1P **389624-66-2P** **389624-67-3P**
389624-68-4P 389624-69-5P **389624-70-8P**
389624-71-9P **389624-72-0P** **389624-73-1P**
389624-74-2P **389624-75-3P** **389624-76-4P**

389624-77-5P 389624-78-6P 389624-79-7P
 389624-80-0P 389624-81-1P 389624-82-2P 389624-83-3P
 389624-84-4P 389624-85-5P 389624-86-6P
 389624-87-7P 389624-88-8P 389624-89-9P
 389624-90-2P 389624-91-3P 389624-92-4P 389624-93-5P 389624-94-6P
 389624-95-7P 389624-96-8P 389624-97-9P 389624-98-0P
 389624-99-1P 389625-00-7P 389625-01-8P 389625-02-9P 389625-03-0P
 389625-04-1P 389625-05-2P 389625-06-3P 389625-07-4P 389625-08-5P
 389625-09-6P 389625-10-9P 389625-11-0P 389625-12-1P 389625-13-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 98-80-6 623-47-2 808-26-4 871-84-1, 1,7-Octadiyne 1118-68-9
 1679-18-1 1765-93-1 5679-00-5 7223-38-3 93501-84-9 127972-02-5
 389625-14-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 113164-67-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 389624-36-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RN 389624-36-6 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(3-methoxyphenyl)ethynyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:51417 HCAPLUS

DN 136:102229

TI Preparation of 7,8 and 9-substituted tetracycline derivatives

IN Nelson, Mark L.; Koza, Darrell


PA Trustees of Tufts College, USA

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C237-00
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 1, 10, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004404	A2	20020117	WO 2001-US20558	20010629
	WO 2002004404	A3	20020613		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	WO 2002012170	A1	20020214	WO 2000-US21366	20000804
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1303479	A2	20030423	EP 2001-950582	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-216656P	P	20000707		
	WO 2000-US21366	W	20000804		
	WO 2001-US20558	W	20010629		
OS	MARPAT 136:102229				
GI					



AB The 7,8 and 9-substituted tetracycline derivs. I (R1 = H, OH; R2, R3 = H, Me, OH; R4 = H, alkenyl, alkynyl, Ph, halophenyl, acyl, phenylalkynyl, heteroaryl, dimethylamino; R5 = H, Ph, nitrophenyl, halo, alkynyl; R6 = H, amino, acetamide, alkynyl; at least one of R4, R5, and R6 is not H) and their pharmaceutically acceptable salts were as antibacterial agents. Thus, tetracycline underwent iodination with NIS to give a mixt. of 7- and 9-iodotetracycline, of which the 7- isomer was treated AsPh3 in presence of Pd(PPh3)2Cl2 and CuI to give 7-phenyltetracycline. I were screened to detn. their in vitro antibacterial min. inhibitory concn. (no data).

ST tetracycline substituted prepn antibacterial

IT Antibacterial agents

Antibiotics

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

IT **263761-03-1P** 295356-13-7P 295356-15-9P 295356-16-0P
 295356-17-1P 330627-27-5P 389139-16-6P 389570-43-8P 389570-44-9P
 389570-45-0P 389570-46-1P 389570-48-3P 389570-49-4P
389570-50-7P 389570-51-8P 389570-52-9P **389570-53-0P**
 389570-54-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

IT 60-54-8, Tetracycline 10592-13-9, Doxycycline hydrochloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

IT 120793-45-5P 161321-34-2P 295356-11-5P 295356-12-6P 330627-20-8P
 389570-41-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

IT 389570-42-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

IT **263761-03-1P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 7,8 and 9-substituted tetracycline derivs. as antibacterial agents)

RN 263761-03-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:208235 HCAPLUS

DN 134:252206

TI Methods of preparing substituted tetracyclines with transition metal-based chemistries

IN Nelson, Mark L.; Rennie, Glen; Koza, Darrell J.

PA Trustees of Tufts College, USA


SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent
 LA English
 IC ICM C07C237-26
 ICS C07C231-12; A61K031-65; A61P031-04
 CC 26-6 (Biomolecules and Their Synthetic Analogs)
 Section cross-reference(s): 10

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019784	A1	20010322	WO 2000-US25040	20000913
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000013993	A	20020702	BR 2000-13993	20000913
	EP 1240133	A1	20020918	EP 2000-961860	20000913
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003509404	T2	20030311	JP 2001-523365	20000913
	US 2002115644	A1	20020822	US 2001-768189	20010123
	US 2002128237	A1	20020912	US 2001-882273	20010615
	US 2002147182	A1	20021010	US 2001-895796	20010629
	US 6500812	B2	20021231		
PRAI	US 1999-154701P	P	19990914		
	US 2000-232091P	P	20000912		
	US 1999-234847	A	19990122		
	US 2000-178519P	P	20000124		
	US 2000-193879P	P	20000331		
	US 2000-193972P	P	20000331		
	US 2000-204158P	P	20000515		
	US 2000-212030P	P	20000616		
	US 2000-212139P	P	20000616		
	US 2000-212471P	P	20000616		
	WO 2000-US16672	W	20000616		
	US 2000-216580P	P	20000707		
	WO 2000-US25040	W	20000913		
OS	CASREACT 134:252206; MARPAT 134:252206				
GI					



AB Substituted tetracycline derivatives were prepared by combining a reactive tetracycline-based precursor and a reactive organic substituent precursor in

the presence of a transition metal catalyst. In one embodiment of the invention, a substituted tetracycline compd. may be prepd. by combining a reactive tetracycline-based precursor compd. such as an arene tetracycline diazonium salt, and a reactive org. substituent precursor, e.g., alkenes, substituted alkenes, vinyl monomers, aroms. and heteroaroms., in the presence of a transition metal catalyst, such as palladium chloride, under conditions such that a tetracycline compd. substituted with the org. substituent is formed. Such compds. may optionally act as intermediates for making other compds., e.g., hydrogenation of unsatd. groups on the substituent. Thus, sancycline-HCl was treated with N-iodosuccinimide in concd. H₂SO₄ to give 61% 7-iodosancycline and 22% 7,9-diodosancycline. 7-Iodosancycline was added to a degassed soln. of MeOH contg. Na₂CO₃ and Pd(OAc)₂ and then 4-chlorophenylbroonic added to give 7-(4-chlorophenyl)sancycline (I). Antibacterial activity of several derivs. was tabulated.

ST tetracycline deriv prepn transition metal chem; antibacterial tetracycline deriv

IT Tetracyclines

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT Transition metals, uses

RL: CAT (Catalyst use); USES (Uses)

(organopalladium catalysts; methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 330627-29-7 330627-30-0 330627-31-1 330627-32-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 263760-99-2P 330627-21-9P 330627-22-0P 330627-26-4P 344771-54-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 3375-31-3 7447-39-4, Cupric chloride, uses 7647-10-1, Palladium chloride 13767-71-0, Cupric iodide 13965-03-2, Bistriphenylphosphinedichloropalladium 14220-64-5, Bisbenzonitriledichloropalladium 15956-28-2, Rhodium (II) acetate 51364-51-3 143006-99-9

RL: CAT (Catalyst use); USES (Uses)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 113164-67-3P 120793-45-5P 161321-34-2P 330627-20-8P 330627-23-1P 330627-25-3P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 263760-98-1P 263761-01-9P **263761-03-1P** 263761-08-6P

330627-24-2P 330627-27-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(methods of prepg. substituted tetracyclines with transition metal-based chemistries)

IT 57-62-5 79-10-7, Propenoic acid, reactions 79-57-2, Oxytetracycline 98-80-6, Phenylboronic acid 100-42-5, Styrene, reactions 127-33-3, Demeclocycline 141-32-2, Butyl acrylate 564-25-0, Doxycycline 751-97-3, Rolitetracycline 808-26-4, Sancycline 914-00-1, Methacycline 992-21-2, Lymecycline 1110-80-1, Pipacycline 1679-18-1, 4-Chlorophenylboronic acid 1765-93-1, 4-Fluorophenylboronic acid

4363-34-2, Etheneboronic acid 4599-60-4, Penimepicycline 6625-20-3,
 Sancycline hydrochloride 10118-90-8, Minocycline 10592-13-9,
 Doxycycline hydrochloride 15590-00-8, Etamocycline 15599-51-6,
 Apicycline 16259-34-0, Penimocycline 16545-11-2, Guamecycline
 24067-17-2, 4-Nitrophenylboronic acid 29144-42-1, Chelocardin
 31770-79-3, Meglucycline 149934-19-0 197958-29-5, 2-Pyridylboronic
 acid

RL: RCT (Reactant); RACT (Reactant or reagent)
 (methods of prepg. substituted tetracyclines with transition
 metal-based chemistries)

IT 171807-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (methods of prepg. substituted tetracyclines with transition
 metal-based chemistries)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ahmad, N; JOUR CHEM SOC PAK 1990, V12(2), P168 HCAPLUS

(2) Koza, D; ORGANIC LETTERS 2000, V2(6), P815 HCAPLUS


IT 263761-03-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (methods of prepg. substituted tetracyclines with transition
 metal-based chemistries)

RN 263761-03-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-
 octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2003 ACS

AN 2000:137899 HCAPLUS

DN 132:279036

TI Synthesis of 7-Substituted Tetracycline Derivatives

AU Koza, Darrell J.

CS Department of Science and Allied Health, Mount Ida College, Newton, MA,
 02459, USA

SO Organic Letters (2000), 2(6), 815-817

CODEN: ORLEF7; ISSN: 1523-7060

PB American Chemical Society

DT Journal

LA English

CC 26-6 (Biomolecules and Their Synthetic Analogs)

AB The synthesis of 7-substituted tetracycline derivs. has been accomplished
 in high yield from 7-halotetracyclines by modified Suzuki and Stille
 coupling protocols. These novel derivs. may serve as a new class of
 tetracycline antibiotics effective against multi-antibiotic-resistant
 bacteria.

ST tetracycline deriv synthesis; sancycline deriv synthesis

IT Stille coupling reaction
Suzuki coupling reaction
(synthesis of 7-substituted tetracycline derivs.)

IT Tetracyclines
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 7-substituted tetracycline derivs.)

IT 98-80-6, Phenylboronic acid 960-16-7, Phenyltributyltin 994-89-8,
Ethynyltributyltin 6625-20-3, Sancycline hydrochloride 7486-35-3,
Vinyltributyltin 17151-47-2, (4-Fluorophenyl)tributyltin 17151-48-3,
(4-Chlorophenyl)tributyltin 28611-39-4, (4-Dimethylaminophenyl)boronic
acid 79048-32-1, (4-Nitrophenyl)tributyltin
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of 7-substituted tetracycline derivs.)

IT 113164-67-3P, 7-Iodosancycline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of 7-substituted tetracycline derivs.)

IT 263760-96-9P 263760-98-1P 263760-99-2P 263761-01-9P 263761-02-0P
263761-03-1P 263761-05-3P 263761-08-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 7-substituted tetracycline derivs.)

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Beereboom, J; J Am Chem Soc 1960, V82, P1003 HCAPLUS
- (2) Boothe, J; J Am Chem Soc 1960, V82, P1253 HCAPLUS
- (3) Broschard, R; Science 1949, V109, P199 HCAPLUS
- (4) Brown, A; J Chem Soc, Perkin Tran 1992, V1, P123
- (5) Buchwald, S; J Am Chem Soc 1998, V120, P9722
- (6) Finlay, A; Science 1950, V111, P85 HCAPLUS
- (7) Hlavka, J; J Am Chem Soc 1962, V84, P1426 HCAPLUS
- (8) McCormick, J; Antibiot Ann 1953, P81
- (9) Mitscher, L; The Chemistry of Tetracycline Antibiotics 1978, V9 HCAPLUS
- (10) Nicolaou, K; Tetrahedron Lett 1998, V39, P7665
- (11) Pattenden, G; Synth Lett 1993, P215 HCAPLUS
- (12) Petisi, J; J Med Chem 1962, V5, P538 HCAPLUS
- (13) Redin, G; Antimicrob Agents Chemother 1966, P371 HCAPLUS
- (14) Stille, J; Angew Chem, Int Ed Engl 1986, V25, P508
- (15) van Honweling, C; F D A Papers 1969, P21


IT **263761-03-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 7-substituted tetracycline derivs.)

RN 263761-03-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



=> fil reg

FILE 'REGISTRY' ENTERED AT 12:18:54 ON 29 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0
DICTIONARY FILE UPDATES: 27 APR 2003 HIGHEST RN 506405-59-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STN Note 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d 16 ide can 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 91

L6 ANSWER 5 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 488817-71-6 REGISTRY
CN 2-Naphthacenecarboxamide, 7-(2-chloro-1-hexenyl)-4-(dimethylamino)-9-(1,1-
dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-
1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H39 Cl N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L6 ANSWER 10 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 488817-66-9 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[2-[4-(trifluoromethyl)phenyl]ethenyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C30 H27 F3 N2 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
 Double bond geometry unknown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L6 ANSWER 15 OF 91 REGISTRY COPYRIGHT 2003 ACS
 RN 488817-59-0 REGISTRY
 CN 2-Naphthacenecarboxamide, 7-(2-chloro-3-hydroxy-1-propenyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H25 Cl N2 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
 Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L6 ANSWER 20 OF 91 REGISTRY COPYRIGHT 2003 ACS
 RN 488817-25-0 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H26 N2 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L6 ANSWER 25 OF 91 REGISTRY COPYRIGHT 2003 ACS
 RN 488815-47-0 REGISTRY
 CN 2-Propenoic acid, 3-[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H35 N3 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
 Double bond geometry unknown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L6 ANSWER 30 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 460069-76-5 REGISTRY
CN 2-Naphthacenecarboxamide, 7-[(1E)-2-(4-chlorophenyl)ethenyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H27 Cl N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:244598

L6 ANSWER 35 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 459809-43-9 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7,9-bis[(4-methoxyphenyl)ethynyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C39 H34 N2 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:247552

L6 ANSWER 40 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 389624-78-6 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(1-pentynyl)-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C26 H28 N2 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:244598

REFERENCE 3: 137:244597

REFERENCE 4: 136:102232

L6 ANSWER 45 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 389624-65-1 REGISTRY

CN 2-Naphthacenecarboxamide, 7-[(1Z)-2-chloro-1-hexenyl]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C27 H31 Cl N2 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)

3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 137:244597

REFERENCE 3: 136:102232

L6 ANSWER 50 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 389624-53-7 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(1E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C30 H27 F3 N2 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 136:102232

L6 ANSWER 55 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 389624-46-8 REGISTRY

CN 2-Naphthacenecarboxamide, 7-(3-amino-3-oxo-1-propenyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C24 H25 N3 O8

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 136:102232

L6 ANSWER 60 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 389624-38-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,10,12,12a-tetrahydroxy-7-(3-methyl-1-pentynyl)-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H30 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118


REFERENCE 3: 137:244598

REFERENCE 4: 137:244597

REFERENCE 5: 136:102232

L6 ANSWER 65 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 389624-27-5 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(3-pyridinylethynyl)-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H25 N3 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118

REFERENCE 3: 136:102232

L6 ANSWER 70 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 389624-18-4 REGISTRY

CN 2-Naphthacenecarboxamide, 7-(1-cyclohexen-1-ylethynyl)-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C29 H30 N2 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


5 REFERENCES IN FILE CA (1957 TO DATE)

5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673
 REFERENCE 2: 137:333118
 REFERENCE 3: 137:244598
 REFERENCE 4: 137:244597
 REFERENCE 5: 136:102232

L6 ANSWER 75 OF 91 REGISTRY COPYRIGHT 2003 ACS
 RN 389624-10-6 REGISTRY
 CN 2-Pentenedioic acid, 4-[[[(6aS,10S,10aS,11aR)-8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-1-naphthacenyl]methylene]-2-iodo-, diethyl ester, (2Z,4Z)- (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H33 I N2 O11
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:333118
 REFERENCE 2: 136:102232

L6 ANSWER 80 OF 91 REGISTRY COPYRIGHT 2003 ACS
 RN 389624-00-4 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(1E)-3-(dimethylamino)-3-oxo-1-propenyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H29 N3 O8
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:333118

REFERENCE 2: 136:102232

L6 ANSWER 85 OF 91 REGISTRY COPYRIGHT 2003 ACS
RN 389623-89-6 REGISTRY
CN 2-Naphthacenecarboxamide, 7-(cyclohexylethynyl)-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H32 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118

REFERENCE 3: 137:244598

REFERENCE 4: 137:244597

REFERENCE 5: 136:102232

L6 ANSWER 90 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 263761-05-3 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethynyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN 7-Ethynylsancycline


FS STEREOSEARCH

MF C23 H22 N2 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)

3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:247552

REFERENCE 2: 137:244598

REFERENCE 3: 132:279036

L6 ANSWER 91 OF 91 REGISTRY COPYRIGHT 2003 ACS

RN 263761-03-1 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-ethenyl-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI)
(CA INDEX NAME)

FS STEREOSEARCH


DR 330627-28-6

MF C23 H24 N2 O7

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 136:102229


REFERENCE 2: 134:252206

REFERENCE 3: 132:279036

=> d 17 ide can 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75

L7 ANSWER 5 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 488820-20-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-(2-methylpropyl)-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H30 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L7 ANSWER 10 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 488819-90-5 REGISTRY
CN 2-Naphthacenecarboxamide, 7-acetyl-4-(dimethylamino)-9-[[2,2-(i-Bu)]]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C29 H37 N3 O8

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L7 ANSWER 15 OF 75 REGISTRY COPYRIGHT 2003 ACS

RN 488818-28-6 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-(4-morpholinyl-oxoacetyl)-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C27 H29 N3 O10

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)


1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L7 ANSWER 20 OF 75 REGISTRY COPYRIGHT 2003 ACS

RN 488817-80-7 REGISTRY
 CN 1-Naphthacenepropanoic acid, 8-(aminocarbonyl)-10-(dimethylamino)-
 5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-5,7-dioxo-, methyl
 ester, (6aS,10S,10aS,11aR)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H28 N2 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

L7 ANSWER 25 OF 75 REGISTRY COPYRIGHT 2003 ACS
 RN 460073-66-9 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
 3,10,12,12a-tetrahydroxy-9-[[[(4-methoxyphenyl)amino]carbonyl]amino]-7-(1-
 methylethyl)-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H36 N4 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:244598

L7 ANSWER 30 OF 75 REGISTRY COPYRIGHT 2003 ACS
 RN 460068-84-2 REGISTRY
 CN 2-Naphthacenecarboxamide, 7-acetyl-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H26 N2 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 138:117673

REFERENCE 2: 137:244598

REFERENCE 3: 137:244597

L7 ANSWER 35 OF 75 REGISTRY COPYRIGHT 2003 ACS
 RN 459809-99-5 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-(1,1-dimethylethyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1Z)-1-(methoxyimino)ethyl]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H35 N3 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:333118


REFERENCE 2: 137:247552

REFERENCE 3: 137:244598

REFERENCE 4: 137:244597

L7 ANSWER 40 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 459809-67-7 REGISTRY
CN 2-Naphthacenecarboxamide, 7,9-diacetyl-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H26 N2 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673


REFERENCE 2: 137:333118

REFERENCE 3: 137:247552

REFERENCE 4: 137:244598

L7 ANSWER 45 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 459809-56-4 REGISTRY
CN 2-Naphthacenecarboxamide, 9-(aminomethyl)-7-butyl-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H33 N3 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:247552

REFERENCE 3: 137:244598

L7 ANSWER 50 OF 75 REGISTRY COPYRIGHT 2003 ACS

RN 459809-46-2 REGISTRY

CN 3-Pyridinecarboxamide, N-[[(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-7-(dimethylamino)-4-ethyl-5, 5a, 6, 6a, 7, 10, 10a, 12-octahydro-1, 8, 10a, 11-tetrahydroxy-10, 12-dioxo-2-naphthacenyl]methyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C30 H32 N4 O8

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118

REFERENCE 3: 137:247552


REFERENCE 4: 137:244598

L7 ANSWER 55 OF 75 REGISTRY COPYRIGHT 2003 ACS

RN 389624-83-3 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-(2-pyridinylacetyl)-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H27 N3 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673


REFERENCE 2: 137:333118

REFERENCE 3: 137:244598

REFERENCE 4: 136:102232

L7 ANSWER 60 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 389624-73-1 REGISTRY
CN 2-Naphthacenecarboxamide, 7-(2-cyclohexylethyl)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H36 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118

REFERENCE 3: 137:244598

REFERENCE 4: 136:102232

L7 ANSWER 65 OF 75 REGISTRY COPYRIGHT 2003 ACS

RN 389624-63-9 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[2-(2-pyridinyl)ethyl]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C28 H29 N3 O7

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 136:102232

L7 ANSWER 70 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 389624-39-9 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-(3-ethylpentyl)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H36 N2 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
5 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118


REFERENCE 3: 137:244598

REFERENCE 4: 137:244597

REFERENCE 5: 136:102232

L7 ANSWER 75 OF 75 REGISTRY COPYRIGHT 2003 ACS
RN 389624-01-5 REGISTRY
CN 2-Naphthacenecarboxamide, 7-[2-(4-aminophenyl)ethyl]-4-(dimethylamino)-
1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-,
(4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H31 N3 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:117673

REFERENCE 2: 137:333118

REFERENCE 3: 136:102232

=> d his

(FILE 'HOME' ENTERED AT 12:12:12 ON 29 APR 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:12:19 ON 29 APR 2003

L1 STR
L2 8 S L1
L3 166 S L1 FUL
SAV TEMP L3 GERSTL895/A
L4 STR L1
L5 5 S L4 SAM SUB=L3
L6 91 S L4 FUL SUB=L3
SAV L6 GERSTL895A/A TEMP
L7 75 S L3 NOT L6

FILE 'HCAPLUS' ENTERED AT 12:15:00 ON 29 APR 2003

L8 9 S L6
L9 6 S L7
L10 6 S L8 AND L9
L11 9 S L8-L10
L12 9 S L11 AND (NELSON ? OR FRECHETTE ? OR VISKI ? OR ISMAIL ? OR BO

FILE 'HCAPLUS' ENTERED AT 12:17:19 ON 29 APR 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 12:17:23 ON 29 APR 2003

L13 3 S L6
L14 2 S L7
L15 3 S L13,L14

L16 FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:17:39 ON 29 APR 2003
12 DUP REM L12 L15 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 12:18:00 ON 29 APR 2003

FILE 'USPATFULL, USPAT2' ENTERED AT 12:18:15 ON 29 APR 2003

FILE 'HCAPLUS' ENTERED AT 12:18:28 ON 29 APR 2003

FILE 'REGISTRY' ENTERED AT 12:18:54 ON 29 APR 2003